Pedro Lowenstein, MD, PhD
Director, Board of Governors Gene Therapeutics Research Institute
Pedro Lowenstein, MD, PhD is Director of the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai and holds the Bram and Elaine Goldsmith Endowed Chair in Gene Therapeutics. Before joining Cedars-Sinai, Dr Lowenstein was awarded the prestigious Lister Institute Professorship of Molecular Medicine and Gene Therapy at the University of Manchester, England, thereby becoming the first ever Professor of Gene Therapy in the United Kingdom.
An internationally recognized leader in gene therapeutics research, Dr. Lowenstein has pioneered cutting-edge breakthroughs in experimental gene therapeutics. He was recently awarded an RO-1 grant from the National Institute of Neurological Disorders of Stroke, the National Institutes of Health that will enable the development of gene therapeutic strategies to treat chronic neurological disorders and generate novel gene therapy vectors.
Dr. Lowenstein is a member of the education committee of the European Society of Gene Therapy and the Neurological Diseases Gene Therapy Committee of the American Society of Gene Therapy. He currently serves in a study section of the National Institute of Neurological Diseases and Stroke, National Institutes of Health.
Dr. Lowenstein has published more than 100 research articles in prestigious medical journals. He is Editor-in-Chief of Current Gene Therapy and a member of the editorial board of Gene Therapy and Molecular Therapy.
Dr. Lowenstein received his medical and doctorate degrees from the University of Buenos Aires. He completed a postdoctoral fellowship at Johns Hopkins University, and he was a Fogarty International fellow at the National Institute of Neurological Diseases and Stroke, National Institutes of Health. Dr. Lowenstein was also an MRC scientist at the University of Oxford, England, and he worked at the Universities of Dundee and Wales.
